In the era of rapidly improving cure rates for hepatitis C infection, has the importance of staging as part of treatment diminished?
A new clinical trial in children is set to begin that will test the blockbuster hepatitis C drug Sovaldi in combination with ribavirin as part of an all-oral regimen.
The US FDA last week approved the combo drug (trade name: Harvoni) for use in the US.
In treatment-naive patients with genotype 4 HCV, treatment with daclatasvir in combination with peginterferon alfa/ribavirin resulted in higher SVR12 rates than treatment with peginterferon alfa/ribavirin alone.
In a somewhat bittersweet result for drugmaker Janssen, a United Kingdom health agency has recommended funding its hepatitis C drug for some patients but not for others.
Increased prevalence of hepatitis C infection among the nation’s young is the subject of a new federally funded study underway in New Mexico.